The Smoothened Homolog pipeline drugs market research report outlays comprehensive information on the Smoothened Homolog targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Smoothened Homolog pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Respiratory, Musculoskeletal Disorders, and Central Nervous System which include the indications Medulloblastoma, Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome), Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis, Fibrosis, Bone Disorders, Amyotrophic Lateral Sclerosis, and Tauopathies. It also reviews key players involved in Smoothened Homolog targeted therapeutics development with respective active and dormant or discontinued products.
The Smoothened Homolog pipeline targets constitutes close to 15 molecules. Out of which, approximately 13 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/ CTA Filed, and Preclinical stages are 2, 4, 1, 2, and 4 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 1, and 1 molecule.
Smoothened Homolog overview
Smoothened homolog (SMO) is a G protein-coupled receptor that probably associates with the patched protein (PTCH) to transduce the hedgehog’s proteins signal. Binding of sonic hedgehog (SHH) to its receptor is thought to prevent normal inhibition by patched of smoothened (SMO). It is required for the accumulation of KIF7 and GLI3 in the cilia.
For a complete picture of Smoothened Homolog’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
